Published in Epilepsia on July 20, 2009
Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr (2011) 1.98
Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus. Ann Neurol (2012) 1.16
Neuroactive steroids for the treatment of status epilepticus. Epilepsia (2013) 0.94
Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration. J Neurosci Methods (2015) 0.92
Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect (2014) 0.81
Combined treatment with diazepam and allopregnanolone reverses tetramethylenedisulfotetramine (TETS)-induced calcium dysregulation in cultured neurons and protects TETS-intoxicated mice against lethal seizures. Neuropharmacology (2015) 0.79
Expression of AMPA receptor subunits in hippocampus after status convulsion. Childs Nerv Syst (2012) 0.78
Somatostatin type-2 receptor activation inhibits glutamate release and prevents status epilepticus. Neurobiol Dis (2013) 0.77
New developments in the treatment of partial-onset epilepsy. Neuropsychiatr Dis Treat (2012) 0.76
Potent anti-seizure effects of D-leucine. Neurobiol Dis (2015) 0.76
Enhanced AMPA receptor-mediated neurotransmission on CA1 pyramidal neurons during status epilepticus. Neurobiol Dis (2017) 0.75
Effects of Low Frequency Stimulation on Spontaneous Inhibitory and Excitatory Post-Synaptic Currents in Hippocampal CA1 Pyramidal Cells of Kindled Rats. Cell J (2016) 0.75
Epilepsy: Novel therapeutic targets. J Pharmacol Pharmacother (2012) 0.75
A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med (2001) 6.53
A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med (1998) 4.31
Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol (2002) 3.36
Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci (2005) 2.75
Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci (1997) 2.51
Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurosci (2005) 2.12
Subunit-specific trafficking of GABA(A) receptors during status epilepticus. J Neurosci (2008) 2.09
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol (1998) 1.90
Molecular targets for antiepileptic drug development. Neurotherapeutics (2007) 1.78
GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron (1993) 1.76
Midazolam and other benzodiazepines. Handb Exp Pharmacol (2008) 1.66
Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Exp Neurol (1988) 1.60
Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron (2005) 1.51
The biochemical basis and pathophysiology of status epilepticus. Neurology (1990) 1.44
Physiology of status epilepticus in primates. Arch Neurol (1973) 1.40
Double-blind study of lorazepam and diazepam in status epilepticus. JAMA (1983) 1.37
Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res (1998) 1.36
A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia (2007) 1.35
N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett (1999) 1.20
Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology (1996) 1.16
Status epilepticus-induced neuronal loss in humans without systemic complications or epilepsy. Epilepsia (2000) 1.15
Ketamine controls prolonged status epilepticus. Epilepsy Res (2000) 1.13
A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology (2002) 1.10
Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res (1993) 1.08
The lower limit of autoregulation: time to revise our thinking? Anesthesiology (1997) 1.07
Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol (2008) 1.05
Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res (2007) 1.01
Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology (2001) 0.99
Excitatory amino acid receptors in the mammalian periphery. Trends Pharmacol Sci (1991) 0.98
Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav (2003) 0.97
NMDA receptor antagonists and limbic status epilepticus: a comparison with standard anticonvulsants. Epilepsy Res (1990) 0.96
Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia (1994) 0.95
Diazepam reduces both arterial blood pressure and muscle sympathetic nerve activity in human. Neurosci Lett (2004) 0.94
Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats. Exp Neurol (1989) 0.94
Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res Bull (2001) 0.92
Refractory status epilepticus: response to ketamine. Neurology (1998) 0.90
The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res (1994) 0.90
The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol (1991) 0.90
The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res (1991) 0.90
Arrhythmia, heart rate variability, and antiepileptic drugs. Epilepsia (1997) 0.89
Allosteric regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines. Neuroscience (1998) 0.89
Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam. Br J Clin Pharmacol (1988) 0.88
A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus. Epilepsy Res (2004) 0.88
Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia (1990) 0.88
Advances in the pathophysiology of status epilepticus. Acta Neurol Scand (2007) 0.84
The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. Psychopharmacology (Berl) (1986) 0.83
Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life Sci (1994) 0.83
Effect of topiramate on the kainate-induced status epilepticus, lipid peroxidation and immunoreactivity of rats. Pol J Pharmacol (2004) 0.83
Fosphenytoin may cause hemodynamically unstable bradydysrhythmias. J Emerg Med (2006) 0.81
SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. J Pharmacol Exp Ther (1999) 0.81
Determinants of ictal epileptiform patterns in the hippocampal slice. Epilepsia (2002) 0.80
Relationship between anticonvulsant activity and plasma level of some 2,3-benzodiazepines in genetically epilepsy-prone rats. Pharmacol Biochem Behav (1998) 0.78
Effect of anticonvulsant drugs on kainic acid-induced epileptiform activity. Exp Neurol (1982) 0.78
Duration of action of GYKI 52466 and its analogues in antiepileptic, anti-ischaemic and muscle relaxant tests. Neurobiology (Bp) (1999) 0.77
Possible involvement of GABA mechanisms in central cardiovascular and respiratory control. Studies on the interaction between diazepam, picrotoxin and clonidine. Med Biol (1977) 0.76
Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology (2012) 2.36
The anticonvulsant activity of acetone, the major ketone body in the ketogenic diet, is not dependent on its metabolites acetol, 1,2-propanediol, methylglyoxal, or pyruvic acid. Epilepsia (2007) 2.20
Molecular targets for antiepileptic drug development. Neurotherapeutics (2007) 1.78
Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol (2006) 1.65
Adult murine skeletal muscle contains cells that can differentiate into beating cardiomyocytes in vitro. PLoS Biol (2005) 1.60
The neuropharmacology of the ketogenic diet. Pediatr Neurol (2007) 1.54
Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. J Neurosci (2002) 1.49
Glia and epilepsy: excitability and inflammation. Trends Neurosci (2013) 1.49
Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci (2003) 1.45
Anticonvulsant activity of androsterone and etiocholanolone. Epilepsia (2005) 1.30
Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia (2004) 1.25
Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp Neurol (2006) 1.23
Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology (2004) 1.21
Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology (2005) 1.20
Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet (2012) 1.15
How theories evolved concerning the mechanism of action of barbiturates. Epilepsia (2012) 1.10
Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics (2009) 1.09
Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res (2010) 1.07
Interactions between deliberation and delay-discounting in rats. Cogn Affect Behav Neurosci (2012) 1.02
New strategies for the identification of drugs to prevent the development or progression of epilepsy. Epilepsy Res (2002) 1.01
Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene. Am J Pathol (2004) 1.00
Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol (2011) 0.97
Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia (2007) 0.96
Issues related to development of new antiseizure treatments. Epilepsia (2013) 0.96
Tetramethylenedisulfotetramine alters Ca²⁺ dynamics in cultured hippocampal neurons: mitigation by NMDA receptor blockade and GABA(A) receptor-positive modulation. Toxicol Sci (2012) 0.95
Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res (2006) 0.94
Characterization of seizures induced by acute and repeated exposure to tetramethylenedisulfotetramine. J Pharmacol Exp Ther (2012) 0.94
Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose. Epilepsia (2010) 0.94
The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics (2014) 0.93
Nontraditional epilepsy treatment approaches. Neurotherapeutics (2009) 0.92
Altered fast and slow inactivation of the N440K Nav1.4 mutant in a periodic paralysis syndrome. Neurology (2012) 0.91
Effects of neurosteroids on epileptiform activity induced by picrotoxin and 4-aminopyridine in the rat hippocampal slice. Epilepsy Res (2003) 0.91
Termination of epileptiform activity by cooling in rat hippocampal slice epilepsy models. Epilepsy Res (2006) 0.90
Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther (2009) 0.89
Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period. Epilepsia (2009) 0.89
Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia (2013) 0.88
Progesterone, neurosteroids, and the hormonal basis of catamenial epilepsy. Ann Neurol (2003) 0.88
Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol (2014) 0.85
Propofol hemisuccinate suppresses cortical spreading depression. Neurosci Lett (2012) 0.85
Point-counterpoint: Do interictal spikes trigger seizures or protect against them? Epilepsy Curr (2007) 0.85
The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors. J Pharmacol Exp Ther (2006) 0.85
Compromised function in the Na(v)1.2 Dravet syndrome mutation R1312T. Neurobiol Dis (2012) 0.85
Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA. J Pharmacol Exp Ther (2007) 0.84
Role of neurosteroids in the anticonvulsant activity of midazolam. Br J Pharmacol (2012) 0.82
11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis. Neuropharmacology (2011) 0.80
Regulation of brain water: is there a role for aquaporins in epilepsy? Epilepsy Curr (2005) 0.80
Seizure protection by intrapulmonary delivery of propofol hemisuccinate. J Pharmacol Exp Ther (2010) 0.79
The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics (2015) 0.79
Mechanisms of action of antiseizure drugs. Handb Clin Neurol (2012) 0.79
Epileptiform activity extinguished by amygdala infusion of the neurotoxin ibotenate in a rat model of temporal lobe epilepsy. J Neurosurg (2002) 0.78
Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala. J Neurochem (2005) 0.78
Astrocytes get in the act in epilepsy. Nat Med (2005) 0.77
Anticonvulsant potencies of the enantiomers of the neurosteroids androsterone and etiocholanolone exceed those of the natural forms. Psychopharmacology (Berl) (2014) 0.76
Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats. J Pharmacol Exp Ther (2013) 0.76
The anticonvulsant activity of acetone does not depend upon its metabolites. Epilepsia (2008) 0.76
Calcium currents burst back: a possible role for dendrites in epileptogenesis. Epilepsy Curr (2008) 0.76
Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis. J Neurosci (2014) 0.75
The ketogenic diet: stoking the powerhouse of the cell. Epilepsy Curr (2007) 0.75
Neurosteroids on the epilepsy chessboard-keeping seizures in check. Epilepsy Curr (2010) 0.75
Support for the NIH public access policy. Science (2006) 0.75
A new policy for disclosure of competing interests. Epilepsy Curr (2011) 0.75
Seizure protection by intrapulmonary delivery of midazolam in mice. Neuropharmacology (2013) 0.75
17beta-Nitro-5alpha-androstan-3alpha-ol and its 3beta-methyl derivative: neurosteroid analogs with potent anticonvulsant and anxiolytic activities. Eur J Pharmacol (2009) 0.75
To Our Readers and the AES Membership. Epilepsy Curr (2011) 0.75